Pure Global
NCT06413459

Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis

Ospedale San Raffaele·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Non-Tuberculous Mycobacterial Pneumonia,Cystic Fibrosis Lung
Drug/Device/Intervention
Luminex; scRNAsec
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Ospedale San Raffaele
Location
Milan, Italy
Timeline & enrollment
Phase
N/A
Start date
Apr 08, 2021
End date
Mar 30, 2027
Enrollment
40 participants
Primary outcome

profile of specific cell populations and expression markers to determine the development and progression of M. abscessus lung disease in patients with CF

Summary

In this project the investigators aim to identify new biological markers by characterizing
 the response/inflammation associated with the development and progression of M. abscessus
 lung disease in patients suffering from cystic fibrosis with the aim of increasing current
 knowledge available on the development and progression of lung disease.

ICD-10 classifications
Pulmonary mycobacterial infectionTuberculosis of lung, without mention of bacteriological or histological confirmationCystic fibrosis with pulmonary manifestationsRespiratory tuberculosis, not confirmed bacteriologically or histologicallyTuberculosis of lung, confirmed by unspecified means
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06413459
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06413459 through Pure Global AI's free database. This phase not specified trial is sponsored by Ospedale San Raffaele and is currently Recruiting. The study focuses on Non-Tuberculous Mycobacterial Pneumonia,Cystic Fibrosis Lung. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.